XVIVO: A major US setback with a period of elevated uncertainty in the US lung market - Redeye

The organic CER growth at -11% is a major negative surprise, and the H1 organic CER growth is 1%. The primary headwind is in the Thoracic segment, which includes the currency headwind (-6%), the Heart headwind ahead of CAP contribution and the EVLP lung headwind. The outlook for the EVLP lung business is, in our view, the main area that will contribute to an extended period of uncertainty during H2 2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1117702/xvivo-a-major-us-setback-with-a-period-of-elevated-uncertainty-in-the-us-lung-market?utm_source=finwire&utm_medium=RSS